Danish pharmaceutical Novo Nordisk acquires German biotech Cardior Pharmaceuticals for up to $1.11bn, focusing on a promising heart failure drug.
Danish pharmaceutical company Novo Nordisk has agreed to acquire German biotech firm Cardior Pharmaceuticals for up to $1.11 billion. The deal aims to strengthen Novo Nordisk's presence in the field of cardiovascular diseases, focusing specifically on a promising drug from Cardior for heart failure. Cardior is developing therapies that target microRNA, a type of molecule that helps regulate protein production in cells. The acquisition is expected to be finalized in the second quarter of 2024.
March 25, 2024
28 Articles